- Home
- ADVM vs TNYA Comparison
ADVM vs TNYA Comparison
Compare ADVM & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- TNYA
- Stock Information
- Founded
- ADVM 2006
- TNYA 2016
- Country
- ADVM United States
- TNYA United States
- Employees
- ADVM N/A
- TNYA N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- ADVM Health Care
- TNYA Health Care
- Exchange
- ADVM Nasdaq
- TNYA Nasdaq
- Market Cap
- ADVM 119.6M
- TNYA 119.2M
- IPO Year
- ADVM 2014
- TNYA 2021
- Fundamental
- Price
- ADVM $4.42
- TNYA $1.08
- Analyst Decision
- ADVM Strong Buy
- TNYA Strong Buy
- Analyst Count
- ADVM 6
- TNYA 5
- Target Price
- ADVM $27.83
- TNYA $17.50
- AVG Volume (30 Days)
- ADVM 168.8K
- TNYA 1.9M
- Earning Date
- ADVM 03-17-2025
- TNYA 03-17-2025
- Dividend Yield
- ADVM N/A
- TNYA N/A
- EPS Growth
- ADVM N/A
- TNYA N/A
- EPS
- ADVM N/A
- TNYA N/A
- Revenue
- ADVM $1,000,000.00
- TNYA N/A
- Revenue This Year
- ADVM N/A
- TNYA N/A
- Revenue Next Year
- ADVM $1,342.84
- TNYA N/A
- P/E Ratio
- ADVM N/A
- TNYA N/A
- Revenue Growth
- ADVM N/A
- TNYA N/A
- 52 Week Low
- ADVM $4.01
- TNYA $0.99
- 52 Week High
- ADVM $29.70
- TNYA $7.01
- Technical
- Relative Strength Index (RSI)
- ADVM 47.04
- TNYA 28.78
- Support Level
- ADVM $4.01
- TNYA $1.43
- Resistance Level
- ADVM $4.58
- TNYA $1.63
- Average True Range (ATR)
- ADVM 0.30
- TNYA 0.09
- MACD
- ADVM 0.05
- TNYA 0.01
- Stochastic Oscillator
- ADVM 63.86
- TNYA 5.66
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.